A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : AIMs / abnormal involuntary movements

[Related PubMed/MEDLINE]
Total Number of Papers: 143
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   AIMs  (>> Co-occurring Abbreviation)
Long Form:   abnormal involuntary movements
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 Distinct anti-dyskinetic effects of amantadine and group II metabotropic glutamate receptor agonist LY354740 in a rodent model: An electrophysiological perspective. LID, SPNs
2020 Genetic deletion of GPR88 enhances the locomotor response to L-DOPA in experimental parkinsonism while counteracting the induction of dyskinesia. GPCR, L-DOPA, LID, MSNs, PD
2020 Ondansetron, a highly selective 5-HT3 receptor antagonist, reduces L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease. L-DOPA, PD
2020 Reciprocal cross-sensitization of D1 and D3 receptors following pharmacological stimulation in the hemiparkinsonian rat. D1R, D3R, DA, PD
2019 Acupuncture Alleviates Levodopa-Induced Dyskinesia via Melanin-Concentrating Hormone in Pitx3-Deficient aphakia and 6-Hydroxydopamine-Lesioned Mice. L-DOPA, LID, PD, PMCH
2019 Chronic administration of the histamine H3 receptor agonist immepip decreases L-Dopa-induced dyskinesias in 6-hydroxydopamine-lesioned rats. D1Rs, H3Rs
2019 Effect of the selective 5-HT2A receptor antagonist EMD-281,014 on L-DOPA-induced abnormal involuntary movements in the 6-OHDA-lesioned rat. L-DOPA, PD
2019 Eltoprazine prevents levodopa-induced dyskinesias by reducing causal interactions for theta oscillations in the dorsolateral striatum and substantia nigra pars reticulate. BG, dStr, LFP, LID, PD, SNr
2019 Riluzole Attenuates L-DOPA-Induced Abnormal Involuntary Movements Through Decreasing CREB1 Activity: Insights from a Rat Model. ---
10  2019 Severity of Dyskinesia and D3R Signaling Changes Induced by L-DOPA Treatment of Hemiparkinsonian Rats Are Features Inherent to the Treated Subjects. D1R, D3-R, L-dopa, LID, MFB, PD, SNr
11  2018 Nociceptive Response to L-DOPA-Induced Dyskinesia in Hemiparkinsonian Rats. LID, PD
12  2018 Striatal norepinephrine efflux in l-DOPA-induced dyskinesia. DA, DBH, LID, NE, PD
13  2018 The combination of the opioid glycopeptide MMP-2200 and a NMDA receptor antagonist reduced l-DOPA-induced dyskinesia and MMP-2200 by itself reduced dopamine receptor 2-like agonist-induced dyskinesia. D1R, D2R, DA, LAO, LID, NMDAR, PD
14  2017 Adenosine A2A Receptor Gene Knockout Prevents l-3,4-Dihydroxyphenylalanine-Induced Dyskinesia by Downregulation of Striatal GAD67 in 6-OHDA-Lesioned Parkinson's Mice. A2AR, GAD, KO, l-DOPA, LID, PD
15  2017 Antidyskinetic Effects of MEK Inhibitor Are Associated with Multiple Neurochemical Alterations in the Striatum of Hemiparkinsonian Rats. ARNT, ERK, LID, MEK, PD, TH
16  2017 Effects of a combination treatment of KD5040 and L-dopa in a mouse model of Parkinson's disease. CREB, DARPP-32, ENK, ERK, l -dopa, LID, LL, MPTP, PD, SP
17  2017 Involvement of the bed nucleus of the stria terminalis in L-Dopa induced dyskinesia. dlBST, L-DOPA, PD
18  2017 Levodopa-induced abnormal involuntary movements correlate with altered permeability of the blood-brain-barrier in the basal ganglia. BBB, GP
19  2016 Amelioration of L-Dopa-Associated Dyskinesias with Triterpenoic Acid in a Parkinsonian Rat Model. L-Dopa, OA
20  2016 Antidyskinetic Effect of 7-Nitroindazole and Sodium Nitroprusside Associated with Amantadine in a Rat Model of Parkinson's Disease. L-DOPA
21  2016 Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous l-DOPA delivery in the 6-OHDA model of Parkinson's disease. DOPAp, IR, LID, LPS, PD
22  2016 Effects of L-dopa priming on cortical high beta and high gamma oscillatory activity in a rodent model of Parkinson's disease. LFP, PD
23  2016 Gadd45beta ameliorates L-DOPA-induced dyskinesia in a Parkinson's disease mouse model. Gadd45beta, L-DOPA, LID, PD
24  2016 In vivo characterization of a novel dopamine D3 receptor agonist to treat motor symptoms of Parkinson's disease. L-dopa, LID, PD
25  2016 Inhibiting Lateral Habenula Improves L-DOPA-Induced Dyskinesia. L-DOPA, LHb
26  2016 Modulation of serotonergic transmission by eltoprazine in L-DOPA-induced dyskinesia: Behavioral, molecular, and synaptic mechanisms. L-DOPA, LTP, PD, SPNs
27  2016 Palmitoyl Serotonin Inhibits L-dopa-induced Abnormal Involuntary Movements in the Mouse Parkinson Model. FAAH, L-DOPA, LID, PD
28  2016 Repetitive transcranial magnetic stimulation (rTMS) improves behavioral and biochemical deficits in levodopa-induced dyskinetic rats model. GDNF, L-dopa, PD, rTMS, TH
29  2016 Validation of an improved scale for rating l-DOPA-induced dyskinesia in the mouse and effects of specific dopamine receptor antagonists. LID
30  2016 Yokukansan, a Traditional Japanese Medicine, Enhances the L-DOPA-Induced Rotational Response in 6-Hydroxydopamine-Lesioned Rats: Possible Inhibition of COMT. 3-MT, COMT, DA, L-DOPA, YKS
31  2015 Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats. CPZ, LID, PD, PPAR, RGZ, TRPV1
32  2015 Effect of simvastatin on L-DOPA-induced abnormal involuntary movements of hemiparkinsonian rats. L-DOPA, LID, MAPK, PD
33  2015 Effects of prolonged neuronal nitric oxide synthase inhibition on the development and expression of L-DOPA-induced dyskinesia in 6-OHDA-lesioned rats. DA, L-DOPA, NADPH-d, nNOS, NO
34  2015 Evidence for a role for alpha6(∗) nAChRs in l-dopa-induced dyskinesias using Parkinsonian alpha6(∗) nAChR gain-of-function mice. LIDs, nAChRs, WT
35  2015 Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease. L-dopa, LID, PD, SP
36  2015 L-745,870 reduces the expression of abnormal involuntary movements in the 6-OHDA-lesioned rat. L-DOPA, MPTP
37  2015 Levetiracetam Ameliorates L-DOPA-Induced Dyskinesia in Hemiparkinsonian Rats Inducing Critical Molecular Changes in the Striatum. LID, p-DARPP-32
38  2015 NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat. PD
39  2015 NR2B antagonist CP-101,606 inhibits NR2B phosphorylation at tyrosine-1472 and its interactions with Fyn in levodopa-induced dyskinesia rat model. L-dopa, NMDAR
40  2015 The combination of lithium and l-Dopa/Carbidopa reduces MPTP-induced abnormal involuntary movements (AIMs) via calpain-1 inhibition in a mouse model: Relevance for Parkinson׳s disease therapy. BS, HAT, L-dopa, PD, ST, TH
41  2014 Differential effects of the NMDA receptor antagonist MK-801 on dopamine receptor D1- and D2-induced abnormal involuntary movements in a preclinical model. D1R, D2R, LAO, LID, NMDA, PD
42  2014 Effects of prolonged selective serotonin reuptake inhibition on the development and expression of L-DOPA-induced dyskinesia in hemi-parkinsonian rats. DA, LID, PD
43  2014 Overexpression of the dopamine D3 receptor in the rat dorsal striatum induces dyskinetic behaviors. EGFP, LID, PD
44  2014 RGS4 is involved in the generation of abnormal involuntary movements in the unilateral 6-OHDA-lesioned rat model of Parkinson's disease. GPCR, PD, RGS
45  2014 The NK1 receptor antagonist N-acetyl-L-tryptophan reduces dyskinesia in a hemi-parkinsonian rodent model. LID, NAT, SP
46  2013 5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model. 5-HTP, LID
47  2013 Abnormal involuntary movement (AIM) expression following D2 dopamine agonist challenge is determined by the nature of prior dopamine receptor stimulation (priming) in 6-hydroxydopamine lesioned rats. AIM, APO, QUIN
48  2013 alpha4beta2 Nicotinic receptors play a role in the nAChR-mediated decline in L-dopa-induced dyskinesias in parkinsonian rats. ---
49  2013 Anti-dyskinetic effect of the neuronal nitric oxide synthase inhibitor is linked to decrease of FosB/deltaFosB expression. 7-NI, l-DOPA, nNOS, NOS, PD
50  2013 Effects of 5-HT1A receptor stimulation on D1 receptor agonist-induced striatonigral activity and dyskinesia in hemiparkinsonian rats. 5-HT1AR, D1R, GAD, PD, PPD
51  2013 Intrastriatal injections of KN-93 ameliorates levodopa-induced dyskinesia in a rat model of Parkinson's disease. CaMKII, LID, PCR, PD, pGluR1S845
52  2013 l-dopa-induced dyskinesias in unilateral 6-hydroxydopamine-lesioned rats are not modified by excitotoxic lesion of the entopeduncular nucleus and substantia nigra pars reticulata. EP, LIDs, SNr
53  2013 Modulating mGluR5 and 5-HT1A/1B receptors to treat l-DOPA-induced dyskinesia: effects of combined treatment and possible mechanisms of action. LID, mGluR5
54  2013 Multiple CNS nicotinic receptors mediate L-dopa-induced dyskinesias: studies with parkinsonian nicotinic receptor knockout mice. nAChRs
55  2013 Role of movement in long-term basal ganglia changes: implications for abnormal motor responses. PD
56  2013 The effect of piribedil on L-DOPA-induced dyskinesias in a rat model of Parkinson's disease: differential role of alpha(2) adrenergic mechanisms. AD, FD, LD, OD, PD
57  2013 Thoughts on selected movement disorder terminology and a plea for clarity. ---
58  2012 Amphetamine-induced dyskinesia in the transplanted hemi-Parkinsonian mouse. ---
59  2012 Anti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson's disease: role of NMDA vs. 5-HT1A receptors. L-dopa, NMDA, PD
60  2012 Controlled-release levodopa methyl ester/benserazide-loaded nanoparticles ameliorate levodopa-induced dyskinesia in rats. ALO, LDME
61  2012 Effect of chronic L-dopa or melatonin treatments after dopamine deafferentation in rats: dyskinesia, motor performance, and cytological analysis. ---
62  2012 Effects of noradrenergic denervation on L-DOPA-induced dyskinesia and its treatment by alpha- and beta-adrenergic receptor antagonists in hemiparkinsonian rats. FAS, L-DOPA, LID, NE, PD
63  2012 Imaging DA release in a rat model of L-DOPA-induced dyskinesias: a longitudinal in vivo PET investigation of the antidyskinetic effect of MDMA. DA, L-DOPA, LID, MDMA
64  2012 In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to L-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels. ---
65  2012 Levodopa/benserazide microspheres reduced levodopa-induced dyskinesia by downregulating phosphorylated GluR1 expression in 6-OHDA-lesioned rats. AMPA, LID, PD, PENK
66  2012 Role for alpha6 nicotinic receptors in l-dopa-induced dyskinesias in parkinsonian mice. nAChRs
67  2012 Striatal inhibition of calpains prevents levodopa-induced neurochemical changes and abnormal involuntary movements in the hemiparkinsonian rat model. L-DOPA, LID, PD
68  2012 The cannabinoid agonist WIN55212-2 decreases L-DOPA-induced PKA activation and dyskinetic behavior in 6-OHDA-treated rats. L-dopa, PD, PKA
69  2011 Amantadine attenuates levodopa-induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels. ---
70  2011 An improved model to investigate the efficacy of antidyskinetic agents in hemiparkinsonian rats. ---
71  2011 Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease. LPS, MPTP, PD
72  2011 BN82451 attenuates L-dopa-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease. LID, PD
73  2011 Context-driven changes in L-DOPA-induced behaviours in the 6-OHDA lesioned rat. ---
74  2011 Evaluation of the D3 dopamine receptor selective agonist/partial agonist PG01042 on L-dopa dependent animal involuntary movements in rats. i.p
75  2011 Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease. MFB, SN
76  2011 Induction and expression of abnormal involuntary movements is related to the duration of dopaminergic stimulation in 6-OHDA-lesioned rats. PD
77  2011 L-DOPA-induced dyskinesia in hemiparkinsonian rats is associated with up-regulation of adenylyl cyclase type V/VI and increased GABA release in the substantia nigra reticulata. ---
78  2011 Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats. D1R
79  2011 Nicotine reduces L-DOPA-induced dyskinesias by acting at beta2* nicotinic receptors. nAChR
80  2011 Nitric Oxide Synthase Inhibitor Improves De Novo and Long-Term l-DOPA-Induced Dyskinesia in Hemiparkinsonian Rats. nNOS
81  2011 Positive association between striatal serotonin level and abnormal involuntary movements in chronic L-DOPA-treated hemiparkinsonian rats. 5-HT, DA, LID
82  2011 Role of dopamine D3 and serotonin 5-HT 1A receptors in L: -DOPA-induced dyskinesias and effects of sarizotan in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. i.p
83  2011 Role of the primary motor cortex in L-Dopa-induced dyskinesia and its modulation by 5-HT1A receptor stimulation. 5-HT1AR, DA, LID, MFB, PFC
84  2011 Striatal dopaminergic fiber recovery after acute L-DOPA treatment in 6-hydroxydopamine (6-OHDA) lesioned rats. DA, MFB, SNpc, TH
85  2011 The involvement of RGS9 in l-3,4-dihydroxyphenylalanine-induced dyskinesias in unilateral 6-OHDA lesion rat model. DA, L-DOPA, LID, PD
86  2010 Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease. AMPA, LID, PD
87  2010 MK-801 inhibits L-DOPA-induced abnormal involuntary movements only at doses that worsen parkinsonism. L-dopa, NMDA
88  2010 Nicotinic receptor-mediated reduction in L-DOPA-induced dyskinesias may occur via desensitization. ---
89  2010 Pre-treatment with dopamine agonists influence L-dopa mediated rotations without affecting abnormal involuntary movements in the 6-OHDA lesioned rat. ---
90  2010 The effects of cannabinoid drugs on abnormal involuntary movements in dyskinetic and non-dyskinetic 6-hydroxydopamine lesioned rats. ---
91  2010 The roles of striatal serotonin and L -amino-acid decarboxylase on L-DOPA-induced Dyskinesia in a Hemiparkinsonian rat model. 5-HT, DA, LID, PD, TH
92  2010 The selective D(3) receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect L-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned rats. ---
93  2009 Amphetamine-induced abnormal movements occur independently of both transplant- and host-derived serotonin innervation following neural grafting in a rat model of Parkinson's disease. ---
94  2009 Assessment of symptomatic and neuroprotective efficacy of Mucuna pruriens seed extract in rodent model of Parkinson's disease. MP, MPTP
95  2009 Contribution of the striatum to the effects of 5-HT1A receptor stimulation in L-DOPA-treated hemiparkinsonian rats. 5-HT1AR, L-DOPA, PPD
96  2009 Evaluation of D2 and D3 dopamine receptor selective compounds on L-dopa-dependent abnormal involuntary movements in rats. LID
97  2009 Evaluation of the D3 dopamine receptor selective antagonist PG01037 on L-dopa-dependent abnormal involuntary movements in rats. i.p, s.c
98  2009 Oral creatine supplementation attenuates L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rats. L-dopa, LID
99  2009 Pharmacological analysis demonstrates dramatic alteration of D1 dopamine receptor neuronal distribution in the rat analog of L-DOPA-induced dyskinesia. ---
100  2009 Serotonin 1B receptor stimulation reduces D1 receptor agonist-induced dyskinesia. L-DOPA